



Research Article

Hipocretinergic/Orexinergic System and its Role in Drug Addiction: A Narrative Review

Carlos Arturo Cassiani Miranda^{1*}, Eduard Fabian Arraut Camargo², Alexander Blanco Palomino³ and Adriana Marcela Porras Saldarriaga³

¹Magister in drug addiction, Neurosciences Research Group, Universidad de Santander (UDES), Bucaramanga, Colombia

²Magister in drug addiction, Universidad de Santander (UDES), Psychiatrist Hospital San Camilo, Bucaramanga, Colombia

³Magister in drug addiction, Universidad de Santander (UDES), Bucaramanga, Colombia

Abstract

Background

Addiction treatment commonly presents therapeutic failures. In recent decades, there has been a growing interest in neuropeptides and their role in regulating the different phases of the addictive process. Such neuropeptides include Orexin, also known as hypocretin.

Objective

The objective of this review is to analyze the recent evidence on the orexinergic system, its role in addiction reinforcement and recurrence, and its therapeutic implications.

Methods

A PubMed, Ebsco, Lilacs and SciELO search was performed using MeSH terms based on the title. Articles in English, Spanish, and Portuguese were included.

Results

The orexinergic system is involved in the incubation of drug seeking after a protracted abstinence period. Orexin and glutamate in VTA are necessary simultaneously for the reinstatement of cue and stress-induced cocaine and alcohol consumption.

*Corresponding author: Carlos Arturo Cassiani Miranda, Magister in drug addiction, Neurosciences Research Group, Universidad de Santander (UDES), Bucaramanga, Colombia, Tel: +57 3184455273; E-mail: ccassianim@mail.udes.edu.co/ kassio30@hotmail.com

Citation: Miranda CAC, Camargo EFA, Palomino AB, Saldarriaga AMP (2019) Hipocretinergic/Orexinergic System and its Role in Drug Addiction: A Narrative Review. J Addict Addictv Disord 6: 28.

Received: May 27, 2019; **Accepted:** July 12, 2019; **Published:** July 22, 2019

Copyright: © 2019 Miranda CAC. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Conclusion

The orexinergic system is key in the drug reward and seeking pathways and is a therapeutic target for future drug therapies in addictive disorders. A better understanding of this system will allow effective interventions to prevent relapse in drug addicts.

Keywords: Hypothalamus; Orexin; Relapse; Review; Reward; Substance related disorders

Introduction

Psychoactive substance use disorders PSUD are characterized by compulsive drug-seeking and ingestion, loss of control in suppressing continued substance use, and negative emotional states when the drug is not available [1]. It is considered a chronic disease with a high relapse rate that may be aroused by the substance itself, re-exposure to drug-related cues, and/or stressful events following a period of withdrawal [2]. Addicts are persistently vulnerable to relapse in drug use following months or even years of abstinence, and relapse is considered the most important problem in addiction treatment [3]. Treatment for addiction to substances such as cocaine and heroin, often presents treatment failures and a high percentage of addicts relapse after a period of abstinence that can last days or years [4,5]. Given the lack of adequate treatment to avoid relapse, addiction to PAS is an enormous social, economic, and medical burden all over the world [6,7]. Neuroanatomical substrates and neurochemical mechanisms associated to relapse have been widely studied over the past 15 years; however, we still lack full understanding of the underlying neurobiological basis and there are important knowledge gaps with regards to the topic. Recent decades have witnessed a growing interest in neuropeptides and their role in the regulation of the different phases of the addictive process [8], among which orexins or hypocretins, that seem to play a central role in the regulation of the reinforcing effects of PAS, as well as in withdrawal and relapse [9,10]. Thus, the pharmacological management of the system represents a potential therapeutic target for the treatment of patients with PSUD [11]. Over the past five years, there has been a significant increase in research work that has attempted to clarify the role of orexins in the different facets of the substance-addiction process. This has made it necessary to update and reexamine the evidence in order to make advances in terms of the neurobiology of addictions [7]. As such, the purpose of this narrative review is to analyze the recent evidence on the role of the orexinergic system in addiction reinforcement and recurrence together with the therapeutic implications of this knowledge.

Materials and Methods

For this narrative review, a search was undertaken in PubMed, initially of original works on animals and humans that describe the neurobiological mechanisms of addictive behavior and, secondly, of articles from the first publication by De Lecea and Sakurai in 1998 who described the role played by orexins in animal models and clinical trials used to assess the role of substances that modify the orexinergic system in the treatment of PAS addiction. For the first phase

of the search, the following keywords were used: Addict* or “Substance-Related Disorders” or “behavior, addictive” or “drug addiction” and “neurobiology” and all related MeSH terms. For the second phase, the following keywords were used: “orexins/hypocretins” and addict* or “Substance-Related Disorders” or “addictive behavior” or “drug addiction” and all related MeSH terms. The search included articles in English, Spanish, and Portuguese published up until December 2016. Articles on addiction to alcohol, nicotine, amphetamines/cocaine, and opioids were included as were experimental studies on animals that examine the role of orexins in the different phases of the addictive process. Articles related to the topic, which appear in Pubmed and the references of interest found in each of the articles included were also traced.

A PubMed search was conducted, adapted to the search criteria of databases Ebsco, Lilacs, and SciELO. Review articles on the topic were excluded. A qualitative analysis was conducted involving the results of the most relevant articles in terms of the role of orexin in the addictive process from the perspective of self-administration/extinction/reinstatement, conditioned place preference and locomotion animal models that are the most frequently used in research on addictions.

Results

Orexins and their physiological action

Orexin A and Orexin B (hypocretin 1 and hypocretin 2) are recently discovered peptides produced based on the prepro-orexin molecule synthesized only in hypothalamic neurons [12]. Since its almost simultaneous discovery by Lecea et al., and Sakurai et al., in 1998 [13,14], a considerable number of studies have been carried out to characterize this new system of neuropeptides. Orexin A in mammals is a peptide with 33 amino acids with two interchain disulfide bridges, a molecular weight of 3562 Da, a pyroglutamyl residue in its extreme N-terminal and amidated in its extreme C-terminus (both typical neuropeptide terminals). The primary structure of Orexin A is completely conserved among humans, rats, mice, pigs and cows; whereas Orexin B is a 28 amino acid polypeptide with an amidated C-terminus and a molecular weight of 2937 Da, with 46% de homology (13/28 a.a) compared to the amino acid sequence of Orexin A [15]. Both Orexin A and Orexin B are peptides derived from a common precursor: Prepro-orexin, codified by a gene composed of two exons and one intron that separates them, located in chromosome 17q21 in humans. Prepro-orexin is a polypeptide of 130-131 amino acid residues (depending on the species-131 in humans), with a typical secretory signal sequence in its extreme N-terminal and cleaved to the mature forms of Orexins A and B [16]. Sakurai et al., also characterized 2 metabotropic receptors for this system, called Ox1R and Ox2R. Ox1R is attached exclusively to the Gq protein, whereas Ox2R can be joined to both Gi/o and Gq proteins [17]. Although Orexin 2 has the same affinity for both receptors, the affinity of Orexin 1 is 10-fold higher for Ox1R than for Ox2R [14]. Orexin neurons are widely projected throughout the neuro-axis, including innervation of the prefrontal cortex, hippocampus, thalamus, midbrain, and the spinal cord [18,19]. Similarly, the two orexin receptors are widely distributed throughout the Central Nervous System (CNS), but they are regionally selective [20,21]. This complex distribution of their projections allows the orexins to participate in a variety of homeostatic functions: Predominantly eating behavior and arousal [22,23]. The growing interest to study the

actions of the orexinergic system has led to the development of orexin receptor antagonists, that have been used in different experimental studies to clarify the pharmacological effects of the neuropeptides [24,25]; among them the orexin receptor antagonist A SB334867 [26], and the dual Orexin A and B receptor antagonist Almorexant [27].

This system was the object of great interest in the years following its discovery when it was discovered that the dysfunction of this system was strongly associated to symptoms of narcolepsy in animals [28-30] and subsequent works involving humans showed that patients with narcolepsy had a small quantity of orexin in their Cerebrospinal Fluid (LCR), and presented a loss of most of their orexinergic neurons [31]. With these findings, the interest in orexins focused on the activation or arousal and maintenance of a state of alert. However, the potential role played by the orexins in their wake process was evident since one of the first publications following its discovery. Sakurai et al., reported that the administration of Orexin A or Orexin B inside the lateral ventricle produced foraging in rats, which is precisely why they were denominated “orexins”, given their appetite stimulating effect [14]. The first report on the possible role of orexins in addictions appeared in 2003, when Georgescu et al., demonstrated that orexinergic neurons participated in opioid withdrawal when finding that orexin-deficient mice presented reduced naloxone-induced morphine withdrawal symptoms [32]. This was later confirmed by Sharf et al., in 2008 by demonstrating that the selective blockage of the Orexin 1 receptor with SB334867 prior to naloxone administration significantly reduced withdrawal symptoms [33]. This and other subsequent findings drove various research groups to assess the possible role of this new system of neuropeptides in their reinforcement and substance abuse [34]. This function of the orexins associated with reinforcement may be different to their recognized role in the maintenance of a state of alert and is possibly mediated by a different subpopulation of orexinergic neurons in the lateral hypothalamus [35,36].

A global view of the addiction neurocircuits

Although drug abuse frequently produces differential behavior and presents different pharmacological profiles, a common characteristic that they share is increased dopaminergic mesolimbic activity in acute phases of the addictive process [37]. This circuit, which has been extensively implicated in the reinforcement properties of natural cues (food or sex) and drugs of abuse, consists in dopaminergic projections (DA) from cell bodies in the Ventral Tegmental Area (VTA) towards the limbic structures (amygdala, ventral pallidum, hippocampus, and nucleus accumbens) and cortical areas (Prefrontal Cortex (PFC), Orbitofrontal Cortex (OFC), and anterior cingulate) [38]. These circuits work in parallel, but play different roles in the addictive process [39]. For example, while the Nucleus Accumbens (NAcc) [39] and the ventral pallidum appear to be implicated in the primary reinforcing effects of drugs of abuse [40]; the amygdala, and the ventral and dorsal hippocampus [41], play an important role in the conditioned learning implicated in the addiction process mediating associations with reinforcing cues, which can be particularly important for contextual learning in the addictive process [42].

On the other hand, the PFC, OFC and anterior cingulate regulate the emotional responses, cognitive control, and executive functions [43], in relation to repeated exposure to the drug, leading to cellular adaptations of the glutamatergic pathway that goes from the PFC to the NAcc contributing to the persistence of addictive behaviors [44],

including the reduction of cognitive control and exaggerated responses to drug-associated cues [45]. As mentioned previously, the recurrence of the drug-seeking and substance use behavior following long periods of abstinence, constitute one of the most important problems in relation to the long term treatment of drug addicts [46]. A significant number of factors have been associated to craving (inordinate desire for drug use, anxiety tendency) and relapse, such as exposure to environmental cues previously associated with drug use, negative moods or stress [47-49]. The study of such factors is one of today's tasks for psychiatry and neuroscience, in order to advance knowledge on the disorder and improve treatment response.

The role of orexins in addictions

The orexigenic LH neurons are anatomically related to regions such as the NAc and VTA, which form part of the cerebral reward systems related to drug addiction [50]. It therefore makes sense to think that such neuropeptides play a role in the addiction process.

The animal models that allow an approximation to the symptoms of human addiction have been crucial to our understanding of the neurobiological mechanisms of PAS addiction [51]. These animal models also offer the possibility to assess new therapeutic strategies for the treatment of addictions [52]. To study the role of orexins in the addictive process, researchers have chosen to do so through these experimental models (paradigms) that are broadly used to shed light on the neurobiological mechanisms underlying addictive behavior. The experimental models are as follows:

- Self-administration/extinction/reinstatement;
- Conditioned place preference;
- Locomotor activity.

Self-administration: Drug self administration is an animal model widely used in preclinical research into PAS addiction [53]. Among the different animal models, this one best stimulates the condition of addiction in humans [54,55]. The procedure consists in the implantation of a catheter in an animal's jugular vein, and, following recovery, the animal self administers a drug intravenously according to the protocol of the operative conditioning usually by pressing a lever or rummaging with the nose [56]. Drug infusion usually coincides with sound or light cues that facilitate drug acquisition and acquires the properties of conditioned cues. Self-administration is generally divided into two phases: Acquisition and maintenance [55]. Although there are many variations to the technique, the most commonly used model for relapse following self-administration is the extinction-reinstatement paradigm [54,55]. In this model, once self-administration has been established and maintained, the animals are subjected to a process of response extinction, which means that the drug is discontinued, suppressing the animal's drug-seeking behavior [54]. Once the drug-seeking behavior is extinguished, its reinstatement can be triggered by priming injections of the drug, a cue previously associated to the drug, or by a physical (electric shocks on the paws) or chemical (yohimbine) stressors [57]. Reinstatement following extinction implies the restoration of a concrete operational response, suggesting that this animal model is relevant to understanding relapse in humans [58].

Self-administration and orexins: Orexin 1 infusion into the VTA increased the effects of cocaine and the tonic and phasic signaling of dopamine and increased motivation for the self-administration of

cocaine in progressive testing protocol [59]. Similarly, Orexin A receptor knockout mice presented much lower levels of cocaine self-administration than wild-type mice [60].

A number of studies have assessed the role of the orexinergic system in the acquisition and maintenance of drug self-administration. For cocaine self-administration, Orexin 1 Receptor (OX1R) mediated signaling regulates the ingestion of cocaine depending on the reinforcement protocol. For example, in a Fixed Rate Protocol (FR1), acute systemic administration of the Orexin 1 receptor antagonist (SB-334867) or intra-VTA Orexin A (OXA) administration did not affect cocaine self-administration [59,61]. In addition, chronic treatment with SB-334867 (10mg/kg/day) did not affect the acquisition or maintenance of self-administration under the same FR1 protocol [62]. However, when the rats were assessed using a Progressive Rate Protocol (PR), OX1R blockade by means of systemic administration of SB-334867 (10mg/kg/day) significantly reduced cocaine self-administration, indicating reduced levels of drug-seeking [63-65]. In addition, the intra-VTA administration of SB-334867 reduced OXA cocaine self-administration [66], whereas the intra-VTA administration increased it [59,63]. Given that the cut-off point for self-administration may reflect the cut-off point for the animal's motivation to access the drug, these data indicate the importance of the orexinergic system in this aspect, and that high levels of motivation are needed for consumption. In fact, the lack of effect of SB-334867 on cocaine self-administration under a FR1 protocol suggests that the signals measured by OX1R may not be necessary for cocaine ingestion under conditions of low motivation. This is supported by the observation that SB-334867 induced a dose-dependent decrease of cocaine self-administration under a high demand FR5 protocol [64]. Although OXR1 is implicated to a greater extent than OXR2 in the regulation of dopaminergic signals and cocaine self-administration, a recent study showed that the blockade of both types of receptors significantly reduced the effect of cocaine on dopaminergic signaling and the motivation to consume cocaine [67].

On the other hand, under a FR protocol, a reduction of ethanol [68,69] and nicotine [27], self-administration was observed with SB-334867 as well as an increase in the self-administration of these two substances following intracranial application of OXA [26,70]. More specifically, OXA infusion in NAcc showed a significant dose-dependent increase in alcohol ingestion in Wistar rats [71].

Similarly, systemic SB-334867 injections significantly reduced the cut-off points for the self-administration of ethanol and nicotine under a PR protocol [26,69]. This finding has been correlated to the fact that OXA microinjections in the lateral hypothalamus and the Paraventricular Nucleus (PVN) increased alcohol ingestion [72]. Recent experiments showed that OXR1 blockade reduces alcohol ingestion [73] and that OXR2 blockade with LSN2424100 and the dual antagonism of OX receptors with Alomexant reduces alcohol ingestion in rats [74]. Other experiments with rats showed that Intra-cerebroventricular (ICV) administration of the selective antagonist OXR2 TCS-OX2-29 reduced ethanol self-administration but not sucrose self-administration, and it had no impact on the reinstatement of cue-induced alcohol-seeking behaviors. Furthermore, TCS-OX2-29 microinjections in core NAc core reduced ethanol response, indicating that OXR2 in the NAc can mediate the reinforcing effects of ethanol [75]. Complementarily, the intraperitoneal administration of SB334867 [76], in the prelimbic cortex [77], showed a dose-dependent

decrease in the cue-induced reinstatement of ethanol. In the same way as with cocaine, these data suggest that both ingestion and motivation for ethanol [78,79] and nicotine [26], self-administration are regulated by the orexinergic system [65].

Extinction: On the first day of extinction, the animals typically exhibit explosive activity, with behavioral responses to the same level or higher than those observed during self-administration [80]. The elevated responses can be interpreted as drug-seeking behavior triggered by contexts associated to the drug, despite the lack of its availability or associated cues [81,82]. In rats previously trained for cocaine self-administration, acute pre treatment with SB-334867 on the first day of extinction reduced the explosive result on that day. However, this effect was only observed during the day of the treatment, given that the response to the extinction was similar to that of the animals in the control groups in the following sessions [83]. Sensitivity to the treatment with SB-334867 also depends on the duration of forced withdrawal. Thus, following a day of withdrawal, only a high dose (30mg/kg) of SB-334867 effectively reduced the context-induced cocaine-seeking behavior. With more protracted withdrawal (14 days) or with the extinction of cocaine-seeking behavior in an environment different from the context of self-administration, even lower doses (10 and 20mg/kg) of SB-334867 were effective [83]. These changes indicate that the orexinergic system may be involved in drug-seeking behavior following long periods of withdrawal as the increased cocaine seeking behavior during withdrawal showed significant sensitivity to OX1R antagonism. On the other hand, chronic effects of SB-334867 have been reported during extinction. In this sense, Zhou et al., showed that systemic daily injections of SB-334867 prior to each extinction test facilitates the extinction process and attenuates the cocaine-seeking response through extinction sessions [84].

Reinstatement: Following extinction, the direct activation of the orexinergic system may bring about the reinstatement of a previously extinguished response. In fact, ICV or intra-VTA administration of OXA reinstates cocaine-seeking behavior extinguished in animals with a history of self-administration [85,86]. SB-334867 administration produced a dose-dependent attenuation of the cue-induced reinstatement, but it could not affect cocaine priming-induced reinstatement [61]. In addition, treatment with SB-334867 before a simple Pavlovian conditioning session, during which the cues were passively conditioned with cocaine infusions, did not suppress cue-induced reinstatement of extinguished cocaine seeking response [61]. These results suggest that OX1R mediated signaling is not necessary during the acquisition of cue-related associations, but rather during recovery and expression of cue learning [87]. In this sense, Mahler et al., examined whether orexins and glutamate interact within the VTA to promote the reinstatement of cocaine-seeking behavior in a self-administration protocol. They found that bilateral microinjections of the OX1R SB334867 antagonist or a mixture of AMPA and NMDA receptor antagonists called CNQX/AP-5 reduced the reinstatement of cue-induced cocaine seeking. In contrast, neither the microinjections nor the systemic administration of SB334867 diminished cocaine-precipitated reinstatement. Also, OX1R blockade combined with contralateral VTA glutamate blockade reduced cue-induced reinstatement, indicating that VTA orexin and glutamate are simultaneously necessary for cue-induced reinstatement.

The fact that the orexinergic system is involved in cue-induced reinstatement and not in cocaine-induced reinstatement, indicates

that orexin signaling mediates cue-drug associative learning, but not necessarily the primary reinforcing effects of the drug itself such as cocaine-induced reinstatement. Stress-induced reinstatement is also mediated by the orexin system, and this is supported by the observation that SB-334867 causes dose-dependent blockade of electric shock stress-mediated cocaine-seeking [85]. However, this process seems to be independent of VTA signaling, given that intra VTA SB 334867 did not block the electric shock stress-induced reinstatement [86]. It has been found that the systemic administration of SB-334867 reduced yohimbine chemical stress-induced cocaine-seeking reinstatement [11].

What could explain the difference between the effects of SB on cocaine-seeking reinstatement or its cue-induced self-administration vs. cocaine-induced self-administration? A possible explanation could be that the DA release following morphine administration requires VTA activation, whereas DA release following cocaine use does not [88].

As with other drugs, alcohol intake cue-induced alcohol-seeking reinstatement was reduced through treatment with SB-334867 both immediately and following extinction or protracted withdrawal, which is a model that best simulates alcoholism in humans [70,89,90]. Further more, during reinstatement, alcohol associated cues increased immediate early genes such as Fos in various regions of the brain, including the orexinergic neurons in the Lateral Hypothalamus (LH), and the degree of alcohol-seeking was positively correlated with Fos expression in the Lateral Hypothalamus (LH) [90-92]. SB-334867 also reduced yohimbine stress-induced alcohol-seeking [70,89]. With regards to nicotine-administration, ICV infusion of OXA produced seeking-behavior reinstatement [93], an effect that was blocked by treatment with SB-334867 [94]. However, SB-334867 did not block shock-induced reinstatement [93]. It is possible that the reinstatement of stress-induced nicotine seeking acts through a mechanism that is independent of OX1R activity. However, to prove this, we would require a more complete dose-response study, given that to assess nicotine-seeking only low doses of SB-334867 (5 and 10mg/kg) were used and it has been observed that to attenuate cocaine-seeking reinstatement, doses of 30mg/kg are required [85]. The study also showed an attenuation of the signs of nicotine withdrawal in orexin knockout mice and wild-type mice pretreated with SB334867 [95].

Conditioned place preference: Conditioned Place Preference (CPP) is an animal model widely used to measure the reinforcing effects of drugs of abuse [96-99]. CPP refers to the development of preference for an environment previously associated with non-contingent substance administration [100]. In this model, the animal is given an injection of the drug and is then restricted to the side of the chamber with visual and tactile cues which are different to those on the other side of the chamber, accessible only following placebo administration [101]. Subsequently, in drug-free conditions, the animal is allowed to access both sides of the chamber. An increase in the amount of time spent on the side associated with the substance is an indication of a positive reinforcing effect of the drug [102]. With regards to the orexin system, the CPP has been used primarily to assess orexin mediation in morphine CPP. The acquisition of morphine CPP was associated with increased activity of the orexinergic neurons in the lateral hypothalamus, determined by increased Fos expression [103]. Thus, bilateral excitotoxic lesions of the LH blocked the acquisition of morphine CPP, and the combination of unilateral excitotoxic lesions of the LH by administration of intra-VTA SB-334867 in the contralateral side

also blocked the development of Morphine CPP [104]. Interestingly, the percentage of Fos positive orexinergic neurons revealed a positive correlation with the amount of time spent by the animal in the morphine-associated chamber [104]. Thus, the morphine-, cocaine-, or food-conditioned rats showed a substantial increase of c-Fos expression in LH neurons. Both systemic and intra-VTA administration of SB-334867 reduced morphine CPP expression [104-106] and the reinstatement of morphine CPP mediated by the administration of the pancreatic polypeptide in LH was blocked by the systemic SB-334867 administration [104].

Interestingly, Richardson and Aston-Jones observed that the orexin neurons that project to the VTA display Fos activation with morphine CPP, and this activation increases as morphine abstinence in rats protracts, indicating that VTA is a possible site for orexin action in the reinstatement of preference during protracted morphine withdrawal [107]. This phenomenon was limited to orexin neurons in LH and not to neurons in the perifornical area or the dorsomedial hypothalamus.

More recent works have found that the administration of both orexin receptors antagonists SB334867 and TC5X229 in the NAcc shell significantly reduced stress-induced reinstatement of morphine CPP, but none of the orexin antagonists had an effect on the reinstatement of morphine-induced CPP. These findings indicate that the NAcc shell is an area of the brain through which orexins participate in relapse into stress-induced but not drug-induced morphine consumption [108,109]. It was also observed that the administration of orexin receptor 1 (SB334867) and 2 (TCS OX2 29) antagonists within the dentate gyrus of the hippocampus in rats reduced the reinstatement of drug-induced dose-dependent morphine-seeking but there was no impact on stress-induced reinstatement [110].

As a whole, these data point out the importance of the orexinergic neurons in the LH and their projections to VTA and NAcc in the development and expression of morphine CPP. Normal preference for the side associated with morphine was observed in animals with neurotoxic lesions outside the LH or in which the counter lateral microinjection of orexin receptor antagonist was applied outside the VTA.

Recent studies have identified a new role for the orexinergic system in opioid addiction by observing that intra-VTA SB334867 administration in rats blocked increased morphine-induced plasticity in dopaminergic neurons through the abolishment of an increased rate of glutamatergic receptors AMPA/NMDA, the blockade of increased glutamate release, and inhibition of a change in the number or function of postsynaptic AMPA receptors [111]. These findings constitute a new role for orexins in morphine-induced plasticity in VTA and they provide a mechanism through which orexins can regulate the output of dopaminergic neurons.

These results indicate that the orexinergic neurons in LH are involved in both the conditioned reinforcement process, and in plasticity in VTA associated to the stimulus-response learning of the relationships between the stimulus and the drug [105].

For amphetamine CPP, it has been observed that high doses (30mg/kg) of SB-334867 blocked CPP expression. Interestingly, in contrast to amphetamines and morphine, SB-334867 did not reduce the expression of cocaine-induced place preference [106].

In subsequent experiments with rats, Sartor and Aston-Jones demonstrated that systemic administration of SB334867 reduced cocaine-induced CPP, and that the lateral septum neurons activate the orexinergic neurons of the LH during cocaine-induced CPP suggesting that this circuit is essential for cocaine-induced CPP [112]. It has also been found that the orexin Messenger RNA levels diminish during CPP in Sprague-Dawley (SD) rats [113]. In contrast, in experiments using SD rats, acute cocaine withdrawal provoked increased levels of orexin Messenger RNA in the LH [113]. These results suggest that orexin gene expression in LH is region specific after CPP in SD rats and that increased orexin-gene expression in LH in rats may contribute to the negative emotional states associated to cocaine withdrawal.

Similarly, the acquisition of ethanol CPP was not affected by OX1R blockade with SB-334867 [114]. These differential results for different types of drugs suggest that the reinforcing effects mediated by the orexin system may depend on the unique pharmacological profiles of drugs of abuse and on the fact that non-orexinergic neurotransmission systems may be enough for the acquisition and expression of CPP.

Locomotion: Hyper-locomotion and drug-induced behavioral sensitization are measures that are widely used to assess the effects of acute and repeated drug abuse [115-117]. Drug-Induced Hyper-Locomotion (DIHL) refers to the increased motor activity in the animal following acute drug administration [115-117]. The animals that show the highest initial locomotion response may be more susceptible to developing compulsive drug self-administration [118,119]. In addition, behavioral sensitization may facilitate the acquisition of self-administration or CPP [120-122]. However, while sensitization has been associated to reinstatement of cocaine-seeking behavior, there have been reports of disassociations between the sensitization and reinstatement of cocaine-induced CPP [118,123]. To date, the studies on the role of the orexinergic system in DIHL and sensitization are quite limited. In mice with no history of drug consumption, the systemic administration of SB-334867 (10mg/kg) did not affect their hyper-locomotion induced by acute systemic administration of cocaine at 15mg/kg doses [124]. When a small dose of cocaine was used (10mg/kg), the cocaine-induced hyper-locomotion was blocked by SB-334867 in the three doses usually used (10,20 and 30mg/kg) [84]. However, in rats with a history of cocaine self-administration, even the high dose of SB334867 (30mg/kg) only had a moderate effect on reducing cocaine-induced activity measured by horizontal distance, but it did not affect the total distance covered [61]. For cocaine-induced behavioral sensitization, it was shown that a chronic injection of SB-334867 (10mg/kg) blocks the developments but not the expression of cocaine sensitization [124].

As with other drugs, ethanol-induced hyper activity was attenuated in a dose-dependent manner by pre-treatment with SB-334867 [114]. In this same direction, Macedo et al., observe that chronic ethanol treatment produced behavioral sensitization and increased the number of Fos-immunoreactive orexinergic neurons in mice and that pretreatment with SB334867 blocked the expression of sensitization in mice chronically treated with ethanol [125].

Intracranial infusion of SB-334867 did not affect morphine induced hyper-locomotion activity in the same way as a 30mg/kg dose of SB-334867 did not affect the development or the expression of behavioral sensitization [106,126]. However, acute administration of SB-334867 (30mg/kg) reduced the expression of sensitization to

amphetamines following a period of withdrawal [127]. It has also been shown that SB-334867 reduced dopaminergic reference to NAcc shell evoked by the administration of amphetamine [127] and the activation of orexinergic neurons in hypothalamic regions increased during the amphetamine-induced sensitization [128]. Similarly, the Dual Orexin Receptor Antagonist (DORA) impeded amphetamine-induced behavioral sensitization [129].

All of these findings contribute evidence that allows us to state that the orexin projections of LH to VTA play an important role in the expression of drug preference, and may also be involved in the recurrence of drug-seeking following withdrawal, which opens possible therapeutic paths in considering that the design of medicines that modulate the orexinergic system may provide an alternative to prevent relapse in patients with substance use disorders in rehabilitation [82].

Discussion

Therapeutic implications

Knowledge of the orexin system may be key in explaining the frequently observed relapse in drug addicts following a period of withdrawal, as the exogenous stimulation of orexin neurons in animals reinstates previously extinguished drug-seeking behavior [85,104]. SB-334867-A administration impedes this recovery of drug-seeking behavior in the presence of cues or contexts that were associated with cocaine or heroin, but it does not affect relapse induced by the drug itself [34,130]. These findings provide a scientific base from which to consider OX1R receptors as potential pharmacological targets in the treatment of relapse in alcohol, morphine, or nicotine addiction [130,131].

Orexin SB334867 antagonist administration does not block cocaine seeking induced by cocaine itself. This contrasts with the ability of SB334867 to block environmental cue-induced cocaine seeking. One of the most significant consequences of the studies is that selective orexin receptor antagonists may be used as therapy to prevent relapse and compulsive drug-seeking behavior [132].

If orexin signaling pathway promote craving, then the use of antagonists of one or both orexin receptors should reduce substance

craving and relapse in clinical practice. However orexin antagonists that are currently being developed address mainly sleep disorders and although their kinetics may not be optimal in the treatment of addiction, there are some promising findings. For example, Almorexant, the first Dual Orexin Receptor Agonist (DORA) [133], reduces CPP for cocaine and amphetamines [134]. Almorexant also reduces alcohol consumption in mice and rats in different animal models [74].

However, Simple Orexin Receptor Antagonists (SORA) for orexin 1 [135,136] and orexin 2 receptors [137,138] appear to be more promising in the treatment of addictive disorders [76,78,139,140]. In fact, in preclinical tests with animal models, the pharmacological antagonism of OX1R reduces opioid, psychostimulant, alcohol, and cannabinoid relapse behavior. Similarly, OX2R antagonism has also been shown to reduce opioid and alcohol self-administration [7].

Future directions and problems to solve

Many studies are based on the use of SB334867 to assess the contribution of OX1 mediated signals. However, this antagonist shows poor solubility and may also be limited because of its selectivity; thus, the use of local injections virally-mediated with knock-out strategies for direct manipulation of OX1 should be explored [141]. Future studies that examine the effects of orexin projections on VTA or other semipro regions implicated in the motivated conduct may use optogenetic technology to selectively activate or inactivate these projections in a temporarily controlled manner [142]. Some studies reveal a lack of rigorously validated antibodies for the determination of orexins and their receptors. Collaborative efforts are required to establish a gold standard for the quantitative determination of the peptide [143].

A significant number of new orexin receptor antagonists are being prepared, and it is expected that more ligands will be developed soon to be used in research, as will the first medication approved for use against addictive disorders as has already been achieved for insomnia with the DORA Suvorexant [144]. However, bearing in mind the many interactions of the orexinergic systems with other neuropeptide systems, it is worth asking: What could the collateral effects of these medications be along with their possible new indications? (Table 1).

Reinforcer	Experiment	Observation
Cocaine-Amphetamine	Self-Administration (SA)	Systemic administration of SB334867 reduced lever pressing for cocaine reward [59,62]
		Systemic intra VTA administration of SB334867 reduced cocaine-induced SA [63,65]
		OX1R (SB334867) and OX2R (Almorexant) blockade reduced the dopaminergic signaling and cocaine-induced SA [67]
		VTA infusion of OXA promotes cocaine-induced SA in discrete trial and progressive ratio protocol [59]
		OXA knockout mice showed lower cocaine SA than wild-type mice [60]
		ICV administration of OXA did not alter cocaine-induced SA in rats [61,85]
	Conditioned Place Preference (CPP)	Systemic administration of SB334867 reduced cocaine-induced CPP in rats [112]
		The activation of orexinergic neurons or OXA administration in VTA reinstated reinforcement seeking in a CPP paradigm [104]
		Treatment with SB-334867 reduced context-provoked cocaine-seeking in rats [83]
	Reinstatement	ICV administration of OXA reinstates cocaine-seeking in operant conditioning paradigm [85,86]
		OX1R (SB334867) blockade combined with contralateral glutamate blockade in VTA reduced signal-induced cocaine reinstatement [87]
		SB334867 had no effect on SA established for cocaine, but reduced cocaine-seeking during extinction [84]
	Sensitization	Chronic administration of SB-334867 impeded cocaine-induced behavioral sensitization [124] and SB-334867 reduced amphetamine-induced behavioral sensitization [127]

		SB-334867 reduced amphetamine-induced behavioral sensitization [127]
		A dual orexin receptor-1 antagonist (DORA-1) impeded amphetamine-induced behavioral sensitization [129]
Ethanol	Self-Administration (SA)	ICV administration of selective OX2R antagonist (TCS-OX2-29) reduced ethanol-induced SA in rats [75]
		OX1R antagonism with SB334867, OX2R with LSN2424100, and OX2R dual antagonism with Alomexant reduced alcohol-ingestion in rats [74]
		OXA infusion in NAcc showed a significant increase of dose-dependent alcohol-ingestion in rats [71]
		SB334867 administration reduces ethanol SA in rats [69,70,89]
	Conditioned Place Preference (CPP)	OX2R (JNJ-10397049) blockade attenuates the acquisition, expression, and reinstatement of ethanol-induced CPP [79]
		SB334867 reduces ethanol-provoked activity without altering ethanol-induced acquisition or expression of CPP in mice [114]
	Reinstatement	Intracerebral and systemic administration of SB334867 in rats, showed dose-dependent decrease of cue-induced reinstatement of ethanol [76,77]
		ICV TCS-OX2-29 administration did not alter cue-induced reinstatement of alcohol-seeking [75]
	Sensitization	Systemic administration of JNJ-10397049 reduce ethanol SA in rats [79]
		Large number of Fos positive hypothalamic orexinergic neurons in correlation with contextual cue-associated alcohol availability [91]
SB334867 significantly reduces the reinstatement of yohimbine-induced ethanol-seeking in rats [89]		
Systemic administration of SB334867 reduces ethanol preference and consumption in rats [78]		
OXA microinjections in LH and PVN increase ethanol ingestion [68,72]		
Pretreatment with SB334867 blocked expression of sensitization in mice chronically treated with ethanol [125]		
Morphine/Heroin	Withdrawal	OX1R (SB334867) blockade before naloxone administration attenuates withdrawal symptoms [33]
		OX1R deficient mice showed a reduction in signs of naloxone-precipitated morphine withdrawal [32]
	Self-Administration (SA)	OX1R (SB334867) blockade reduced cocaine SA and (context) cue-induced morphine seeking [130]
	Conditioned Place Preference (CPP)	SB334867 or TCSOX229 administration in NAcc shell reduced reinstatement of stress-induced morphine CPP, but not morphine-induced CPP [108]
		Systemic intra-VTA SB334867 administration reduced expression of morphine-induced CPP [106]
		OX1R knockout mice showed morphine-induced (CPP) intra VTA infusion of SB334867 altered CPP in rats [105]
	Sensitization	OXA microinjections in PVT inhibited morphine-induced locomotion activity in rats [126]
OX1R knockout mice treated with SB334867 and controls showed similar locomotion activity after morphine-administration [106]		
Nicotine	Self-Administration (SA)	Systemic SB334867 administration diminished nicotine SA in mice [26]
		OX1R (SB334867) blockade reduced the reinstatement of nicotine-seeking in mice [94]
		OX1R (SB334867) blockade to OX2R dual blockade (Almoxant) reduced nicotine SA [27]
	Withdrawal	Somatic signs of nicotine withdrawal are attenuated in knockout and wild-type mice pretreated with SB334867 [95]
	Conditioned Place Preference (CPP)	ICV infusion of OX1R reinstated nicotine-seeking behavior previously extinguished mice [93]

Table 1: Summary of studies on the role of orexin in addiction to some psychoactive substances.

Conclusion

The orexinergic system plays an established role in the drug seeking and rewards processes and is a therapeutic target for future drug therapy in addictive disorders. Orexin acts mainly through OX1R to increase the synaptic efficacy of the dopaminergic VTA neurons promoting dopamine release [63,65,124,145,146] which is related to seeking behaviors and reinforcing effects of drugs of abuse. The activation of the orexinergic system by stress may introduce neuroadaptive changes, which may lead to increased susceptibility to drug addiction and relapse. Selective OX1R receptor antagonists such as SB-334867-A or GSK1059865 may help maintain withdrawal and reduce relapse in addictive processes. A greater understanding of this system will probably allow us to design efficient therapeutic interventions that prevent relapses in addicts to drugs of abuse. More studies are needed to shed light on the molecular bases through which these medications manipulate the orexinergic system and modify the reward circuits. There should also be upcoming results to studies in

preclinical phase aimed at treating addiction especially to cocaine and opioids.

Conflicts of Interest

None to declare.

Funding

Author's own resources.

Reference

1. Koob GF (2009) Neurobiological substrates for the dark side of compulsivity in addiction. *Neuropharmacology* 56: 18-31.
2. Everitt BJ (2014) Neural and psychological mechanisms underlying compulsive drug seeking habits and drug memories—indications for novel treatments of addiction. *Eur J Neurosci* 40: 2163-2182.

3. Sinha R (2013) The clinical neurobiology of drug craving. *Curr Opin Neurobiol* 23: 649-654.
4. Hosseini S, Moghimbeigi A, Roshanaei G, Momeniarbat F (2014) Evaluation of drug abuse relapse event rate over time in frailty model. *Osong Public Heal Res Perspect* 5: 92-95.
5. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, et al. (2004) Neurobiological mechanisms in the transition from drug use to drug dependence. *Neurosci Biobehav Rev* 27: 739-749.
6. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, et al. (2013) Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. *Lancet* 382: 1575-1586.
7. Khoo SY, Brown RM (2014) Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? *CNS Drugs* 28: 713-730.
8. Boutrel B (2008) A neuropeptide-centric view of psychostimulant addiction. *Br J Pharmacol* 154: 343-357.
9. Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston-Jones G (2012) Multiple roles for orexin/hypocretin in addiction. *Prog Brain Res* 198: 79-121.
10. Plaza-zabala A, Maldonado R, Berrendero F (2012) The hypocretin / orexin system: Implications for drug reward and relapse. *Mol Neurobiol* 45: 424-439.
11. Zhou L, Sun WL, See RE (2011) Orexin receptor targets for anti-relapse medication development in drug addiction. *Pharm* 4: 804-821.
12. Scammell TE, Winrow CJ (2011) Orexin receptors: Pharmacology and therapeutic opportunities. *Annu Rev Pharmacol Toxicol* 51: 243-266.
13. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, et al. (1998) The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. *Proc Natl Acad Sci USA* 95: 322-327.
14. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, et al. (1998) Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. *Cell* 92: 573-585.
15. Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, et al. (2005) Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. *Neuron* 46: 297-308.
16. Shibata M, Mondal MS, Date Y, Nakazato M, Suzuki H, et al. (2008) Distribution of orexins-containing fibers and contents of orexins in the rat olfactory bulb. *Neurosci Res* 61: 99-105.
17. Zhu Y, Miwa Y, Yamanaka A, Yada T, Shibahara M (2003) Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. *J Pharmacol Sci* 92: 259-266.
18. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, et al. (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. *J Neurosci* 18: 9996-10015.
19. Galas L, Vaudry H, Braun B, Van Den Pol AN, De Lecea L, et al. (2001) Immunohistochemical localization and biochemical characterization of hypocretin/orexin-related peptides in the central nervous system of the frog *Rana ridibunda*. *J Comp Neurol* 429: 242-252.
20. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM (1998) Distribution of orexin receptor mRNA in the rat brain. *FEBS Lett* 438: 71-75.
21. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, et al. (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. *J Comp Neurol* 435: 6-25.
22. Sakurai T (2005) Roles of orexin/hypocretin in regulation of sleep/wakefulness and energy homeostasis. *Sleep Med Rev* 9: 231-241.
23. de Lecea L, Sutcliffe JG (2005) The hypocretins and sleep. *FEBS J* 272: 5675-5688.
24. Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, et al. (2015) A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. *J Pharmacol Exp Ther* 352: 590-601.
25. Kodadek T, Cai D (2010) Chemistry and biology of orexin signaling. *Mol Biosyst* 6: 1366-1375.
26. Hollander JA, Lu Q, Cameron MD, Kamenecka TM, Kenny PJ (2008) Insular hypocretin transmission regulates nicotine reward. *Proc Natl Acad Sci USA* 105: 19480-19485.
27. Lesage MG, Perry JL, Kotz CM, Shelley D, Corrigan WA (2010) Nicotine self-administration in the rat: Effects of hypocretin antagonists and changes in hypocretin mRNA. *Psychopharmacology (Berl)* 209: 203-212.
28. Valencia AMH, Cassiani MCA, Cardona OJC, Villalobos Talero J (2010) El sistema orexinérgico/hipocretinérgico y su rol en los trastornos del sueño Orexinergic (hypocretinergic) system and its role on sleep disorders. *Salud Uninorte Barranquilla (Col)* 26: 285-297.
29. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. *Cell* 98: 437-451.
30. Lin L, Faraco J, Li R, Kadotani H, Rogers W, et al. (1999) The Sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. *Cell* 98: 365-376.
31. Nishino S (2007) The hypothalamic peptidergic system, hypocretin/orexin and vigilance control. *Neuropeptides* 41: 117-133.
32. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, et al. (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. *J Neurosci* 23: 3106-3111.
33. Sharf R, Sarhan M, Dileone RJ (2008) Orexin mediates the expression of precipitated morphine withdrawal and concurrent activation of the nucleus accumbens shell. *Biol Psychiatry* 64: 175-183.
34. Aston-jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, et al. (2010) Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. *Brain Res* 1314: 74-90.
35. Boutrel B, Lecea de L (2008) Addiction and arousal: The hypocretin connection. *Physiol Behav* 93: 947-951.
36. Harris GC, Aston-jones G (2006) Arousal and reward: A dichotomy in orexin function. *Trends Neurosci* 29: 571-577.
37. Feltenstein MW, See RE (2008) The neurocircuitry of addiction: An overview. *Br J Pharmacol* 154: 261-274.
38. Potenza MN (2008) The neurobiology of pathological gambling and drug addiction: An overview and new findings. *Philos Trans R Soc L B Biol Sci* 363: 3181-3189.
39. Koob GF (2008) A role for brain stress systems in addiction. *Neuron* 59: 11-34.
40. Sleipness EP, Jansen HT, Schenk JO, Sorg BA (2008) Time-of-day differences in dopamine clearance in the rat medial prefrontal cortex and nucleus accumbens. *Synapse* 62: 877-885.
41. Mickiewicz AL, Dallimore JE, Napier TC (2009) The ventral pallidum is critically involved in the development and expression of morphine-induced sensitization. *Neuropsychopharmacology* 34: 874-886.
42. Rogers JL, See RE (2007) Selective inactivation of the ventral hippocampus attenuates cue-induced and cocaine-primed reinstatement of drug-seeking in rats. *Neurobiol Learn Mem* 87: 688-692.

43. Fuchs RA, Eaddy JL, Su Z, Bell GH (2007) Interactions of the basolateral amygdala with the dorsal hippocampus and dorsomedial prefrontal cortex regulate drug context-induced reinstatement of cocaine-seeking in rats. *Eur J Neurosci* 26: 487-498.
44. Volkow ND, Wang G, Telang F, Fowler JS, Logan J, et al. (2006) Cocaine cues and dopamine in dorsal striatum: Mechanism of craving in cocaine addiction. *J Neurosci* 26: 6583-6588.
45. Kalivas PW, Volkow ND (2005) The neural basis of addiction: A pathology of motivation and choice. *Am J Psychiatry* 162: 1403-1413.
46. Hearing MC, See RE, McGinty JF (2008) Relapse to cocaine-seeking increases activity-regulated gene expression differentially in the striatum and cerebral cortex of rats following short or long periods of abstinence. *Brain Struct Funct* 213: 215-227.
47. Koya E, Spijker S, Voorn P, Binnekade R, Schmidt ED, et al. (2006) Enhanced cortical and accumbal molecular reactivity associated with conditioned heroin, but not sucrose-seeking behaviour. *J Neurochem* 98: 905-915.
48. Pietro NC Di, Black YD, Kantak KM (2006) Context-dependent prefrontal cortex regulation of cocaine self-administration and reinstatement behaviors in rats. *Eur J Neurosci* 24: 3285-3298.
49. Dayas CV, Xiu L, Simms JA, Weiss F (2007) Distinct patterns of neural activation associated with ethanol seeking: effects of naltrexone. *Biol Psychiatry* 61: 979-989.
50. Sharf R, Sarhan M, Dileone RJ (2010) Role of orexin/hypocretin in dependence and addiction. *Brain Res* 1314: 130.
51. Rømer K, Fjorback LO, Møller A, Lou HC (2014) Applying incentive sensitization models to behavioral addiction. *Neurosci Biobehav Rev* 45: 343-349.
52. Frascella J, Richardson KA, Mclellan GL (2011) Animal models of drug addiction in support of novel therapeutic strategies. *ILAR J* 52: 233-238.
53. Mead AN (2014) Appropriate experimental approaches for predicting abuse potential and addictive qualities in preclinical drug discovery. *Expert Opin Drug Discov* 9: 1281-1291.
54. Epstein DH, Preston KL, Stewart J, Stewart J (2006) Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. *Psychopharmacology (Berl)* 189: 1-16.
55. Bossert JM, Marchant NJ, Calu DJ, Shaham Y (2013) The reinstatement model of drug relapse: Recent neurobiological findings, emerging research topics, and translational research. *Psychopharmacology (Berl)* 229: 453-476.
56. Pautassi RM, Miranda-Morales RS, Nizhnikov M (2015) Operant self-administration of ethanol in infant rats. *Physiol Behav* 148: 87-99.
57. Perry CJ, Zbukvic I, Kim JH, Lawrence AJ (2014) Role of cues and contexts on drug-seeking behaviour. *Br J Pharmacol* 171: 4636-4672.
58. Marchant NJ, Kaganovsky K, Shaham Y, Bossert JM (2015) Role of corticostriatal circuits in context-induced reinstatement of drug seeking. *Brain Res* 1628: 219-232.
59. España RA, Melchior JR, Roberts DCS, Jones SR (2011) Hypocretin 1/orexin A in the ventral tegmental area enhances dopamine responses to cocaine and promotes cocaine self-administration. *Psychopharmacology (Berl)* 214: 415-426.
60. Hollander JA, Pham D, Fowler CD, Kenny PJ (2012) Hypocretin-1 receptors regulate the reinforcing and reward-enhancing effects of cocaine: Pharmacological and behavioral genetics evidence. *Front Behav Neurosci* 6: 47.
61. Smith RJ, See RE, Aston-jones G (2009) Orexin/hypocretin signaling at the orexin 1 receptor regulates cue-elicited cocaine-seeking. *Eur J Neurosci* 30: 493-503.
62. Hutcheson DM, Quarta D, Halbout B, Valerio E, Heidbreder C (2011) Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward. *Behav Pharmacol* 22: 173-181.
63. España RA, Oleson EB, Locke JL, Brookshire BR, Roberts DCS, et al. (2010) The hypocretin-orexin system regulates cocaine self-administration via actions on the mesolimbic dopamine system. *Eur J Neurosci* 31: 336-348.
64. Kenny PJ (2011) Tobacco dependence, the insular cortex and the hypocretin connection. *Pharmacol Biochem Behav* 97: 700-707.
65. Borgland SL, Chang S, Bowers MS, Thompson JL, Vittoz N, et al. (2009) Orexin a/hypocretin-1 selectively promotes motivation for positive reinforcers. *J Neurosci* 29: 11215-11225.
66. Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, et al. (2014) Hypocretin (orexin) facilitates reward by attenuating the anti-reward effects of its cotransmitter dynorphin in ventral tegmental area. *Proc Natl Acad Sci USA* 111: 1648-1655.
67. Prince CD, Rau AR, Yorgason JT, España RA (2015) Hypocretin/orexin regulation of dopamine signaling and cocaine self-administration is mediated predominantly by hypocretin receptor 1. *ACS Chem Neurosci* 6: 138-146.
68. Chen Y, Barson JR, Chen A, Hoebel BG, Leibowitz SF (2014) Hypothalamic peptides controlling alcohol intake: Differential effects on microstructure of drinking bouts. *Alcohol* 48: 657-664.
69. Jupp B, Krivdic B, Krstew E, Lawrence AJ (2011) The orexin 1 receptor antagonist SB-334867 dissociates the motivational properties of alcohol and sucrose in rats. *Brain Res* 1391: 54-59.
70. Lawrence AJ, Cowen MS, Yang H, Chen F, Oldfield B (2006) The orexin system regulates alcohol-seeking in rats. *Br J Pharmacol* 148: 752-759.
71. Mayannavar S, Rashmi KS, Rao YD, Yadav S, Ganaraja B (2014) Effect of orexin a antagonist (SB-334867) infusion into the nucleus accumbens on consummatory behavior and alcohol preference in Wistar rats. *Indian J Pharmacol* 48: 53-58.
72. Schneider ER, Rada P, Darby RD, Leibowitz SF, Hoebel BG (2007) Orexigenic peptides and alcohol intake: Differential effects of orexin, galanin, and ghrelin. *Alcohol Clin Exp Res* 31: 1858-1865.
73. Carvajal F, Alcaraz-Iborra M, Lerma-Cabrera JM, Valor LM, de la Fuente L, et al. (2015) Orexin receptor 1 signaling contributes to ethanol binge-like drinking: Pharmacological and molecular evidence. *Behav Brain Res* 287: 230-237.
74. Anderson RI, Becker HC, Adams BL, Jesudason CD, Rorick-Kehn LM (2014) Orexin-1 and orexin-2 receptor antagonists reduce ethanol self-administration in high-drinking rodent models. *Front Neurosci* 8: 33.
75. Brown RM, Khoo SY, Lawrence AJ (2013) Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats. *Int J Neuropharmacol* 16: 2067-2079.
76. Martin-Fardon R, Weiss F (2014) N-(2-Methyl-6-benzoxazolyl)-N'-1,5-naphthylidene-4-yl urea (SB334867), a hypocretin receptor-1 antagonist, preferentially prevents ethanol seeking: Comparison with natural reward seeking. *Addict Biol* 19: 233-236.
77. Brown RM, Kim AK, Khoo SY, Kim JH, Jupp B, et al. (2016) Orexin-1 receptor signalling in the prelimbic cortex and ventral tegmental area regulates cue-induced reinstatement of ethanol-seeking in iP rats. *Addict Biol* 21: 603-612.
78. Moorman DE, Aston-jones G (2009) Orexin-1 receptor antagonism decreases ethanol consumption and preference selectively in high-ethanol preferring Sprague e Dawley rats. *Alcohol* 43: 379-386.

79. Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, et al. (2011) Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. *Psychopharmacology (Berl)* 215: 191-203.
80. Knackstedt LA, Trantham-davidson HL, Schwendt M (2014) The role of ventral and dorsal striatum mGluR5 in relapse to cocaine-seeking and extinction learning. *Addict Biol* 19: 87-101.
81. Peck JA, Ranaldi R (2014) Drug abstinence: Exploring animal models and behavioral treatment strategies. *Psychopharmacology (Berl)* 231: 2045-2058.
82. Hogarth L, Retzler C, Munaf MR, Tran DMD, Troisi JR, et al. (2014) Extinction of cue-evoked drug-seeking relies on degrading hierarchical instrumental expectancies. *Behav Res Ther* 59: 61-70.
83. Smith RJ, Tahsili-fahadan P, Aston-jones G (2010) Orexin/hypocretin is necessary for context-driven cocaine-seeking. *Neuropharmacology* 58: 179-184.
84. Zhou L, Smith RJ, Do PH, Aston-jones G, See RE (2012) Repeated orexin 1 receptor antagonism effects on cocaine seeking in rats. *Neuropharmacology* 63: 1201-1207.
85. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, et al. (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. *Proc Natl Acad Sci USA* 102: 19168-19173.
86. Wang B, You Z, Wise RA (2009) Reinstatement of cocaine seeking by hypocretin (Orexin) in the ventral tegmental area: Independence from the local corticotropin-releasing factor network. *Biol Psychiatry* 65: 857-862.
87. Mahler SV, Smith RJ, Aston-jones G (2013) Interactions between VTA orexin and glutamate in cue-induced reinstatement of cocaine seeking in rats. *Psychopharmacology (Berl)* 226: 687-698.
88. Aston-jones G, Smith RJ, Moorman DE, Richardson KA (2009) Role of lateral hypothalamic orexin neurons in reward processing and addiction. *Neuropharmacology* 56: 112-121.
89. Richards JK, Simms JA, Steensland P, Taha SA, Borgland SL, et al. (2008) Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats. *Psychopharmacology (Berl)* 199: 109-117.
90. Jupp B, Krstew E, Dezi G, Lawrence AJ (2011) Discrete cue-conditioned alcohol-seeking after protracted abstinence: Pattern of neural activation and involvement of orexin 1 receptors. *Br J Pharmacol* 162: 880-889.
91. Dayas CV, Mcgranahan TM, Martin-fardon R, Weiss F (2008) Stimuli linked to ethanol availability activate hypothalamic cart and orexin neurons in a reinstatement model of relapse. *Biol Psychiatry* 63: 152-157.
92. Hamlin AS, Newby J, McNally GP (2007) The neural correlates and role of D1 dopamine receptors in renewal of extinguished alcohol-seeking. *Neuroscience* 146: 525-536.
93. Plaza-zabala A, Martín-garcía E, Lecea L De, Maldonado R, Berrendero F (2010) Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior. *J Neurosci* 30: 2300-2310.
94. Plaza-Zabala A, Flores Á, Martín-García E, Saravia R, Maldonado R, et al. (2013) A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior. *Neuropsychopharmacology* 38: 1724-1736.
95. Plaza-zabala A, Flores Á, Maldonado R, Berrendero F (2012) Hypocretin/orexin signaling in the hypothalamic paraventricular nucleus is essential for the expression of nicotine withdrawal. *Biol Psychiatry* 71: 214-223.
96. Moaddab M, Hyland BI, Brown CH (2015) Oxytocin enhances the expression of morphine-induced conditioned place preference in rats. *Psychoneuroendocrinology* 53: 159-169.
97. Prast JM, Schardl A, Sartori SB, Singewald N, Saria A, et al. (2014) Increased conditioned place preference for cocaine in high anxiety related behavior (HAB) mice is associated with an increased activation in the accumbens corridor. *Front Behav Neurosci* 8: 441.
98. Kutlu MG, Ortega LA, Gould TJ (2015) Strain-dependent performance in nicotine-induced conditioned place preference. *Behav Neurosci* 129: 37-41.
99. Nygard SK, Klambatsen A, Balouch B, Quinones-Jenab V, Jenab S (2015) Region and context-specific intracellular responses associated with cocaine-induced conditioned place preference expression. *Neuroscience* 287: 1-8.
100. Bardo MT, Bevins RA (2000) Conditioned place preference: What does it add to our preclinical understanding of drug reward? *Psychopharmacology (Berl)* 153: 31-43.
101. Bardo MT, Valone JM, Bevins RA (1999) Locomotion and conditioned place preference produced by acute intravenous amphetamine: Role of dopamine receptors and individual differences in amphetamine self-administration. *Psychopharmacology (Berl)* 143: 39-46.
102. Deroche V, Moal M Le, Piazza PV (1999) Cocaine self-administration increases the incentive motivational properties of the drug in rats. *Eur J Neurosci* 11: 2731-2736.
103. Harris GC, Wimmer M, Randall-thompson JF, Aston-jones G (2007) Lateral hypothalamic orexin neurons are critically involved in learning to associate an environment with morphine reward. *Behav Brain Res* 183: 43-51.
104. Harris GC, Wimmer M, Aston-jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. *Nature* 437: 556-559.
105. Narita M, Nagumo Y, Hashimoto S, Narita M, Khotib J, et al. (2006) Direct involvement of orexinergic systems in the activation of the mesolimbic dopamine pathway and related behaviors induced by morphine. *J Neurosci* 26: 398-405.
106. Sharf R, Guarnieri DJ, Taylor JR, Dileone RJ (2010) Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. *Brain Res* 1317: 24-32.
107. Richardson KA, Aston-jones G (2012) Lateral hypothalamic orexin/hypocretin neurons that project to ventral tegmental area are differentially activated with morphine preference. *J Neurosci* 32: 3809-3817.
108. Qi K, Wei C, Li Y, Sui N (2013) Orexin receptors within the nucleus accumbens shell mediate the stress but not drug priming-induced reinstatement of morphine conditioned place preference. *Front Behav Neurosci* 7: 144.
109. Sadeghzadeh F, Namvar P, Naghavi FS, Haghparast A (2016) Differential effects of intra-accumbal orexin-1 and -2 receptor antagonists on the expression and extinction of morphine-induced conditioned place preference in rats. *Pharmacol Biochem Behav* 142: 8-14.
110. Ebrahimian F, Naghavi FS, Yazdi F, Sadeghzadeh F, Taslimi Z, et al. (2016) Differential roles of orexin receptors within the dentate gyrus in stress-and drug priming-induced reinstatement of conditioned place preference in rats. *Behav Neurosci* 130: 91-102.
111. Baimel C, Borgland SL (2015) Orexin signaling in the VTA gates morphine-induced synaptic plasticity. *J Neurosci* 35: 7295-7303.
112. Sartor GC, Aston-jones GS (2012) A septal-hypothalamic pathway drives orexin neurons, which is necessary for conditioned cocaine preference. *J Neurosci* 32: 4623-4631.

113. Zhou Y, Cui C, Schlussman SD, Choi JC, Ho A, et al. (2008) Effects of cocaine place conditioning, chronic escalating-dose “binge” pattern cocaine administration and acute withdrawal on orexin/hypocretin and preprodynorphin gene expressions in lateral hypothalamus of Fischer and Sprague-Dawley rats. *Neuroscience* 153: 1225-1234.
114. Voorhees CM, Cunningham CL (2011) Involvement of the orexin/hypocretin system in ethanol conditioned place preference. *Psychopharmacology (Berl)* 214: 805-818.
115. Peter W, Pierce RC, Cornish J, Sorg BA (1998) A role for sensitization in craving and relapse in cocaine addiction. *J Psychopharmacol* 12: 49-53.
116. Robinson TE, Kent C (1993) The neural basis of drug craving: An incentive-sensitization theory of addiction. *Brain Res Rev* 18: 247-291.
117. Ferrario CR, Gorny G, Crombag HS, Li Y, Kolb B, et al. (2005) Neural and behavioral plasticity associated with the transition from controlled to escalated cocaine use. *Biol Psychiatry* 58: 751-759.
118. De Vries TJ, Schoffelmeer ANM, Binnekade R, Mulder AH, Vanderschuren LJMJ (1998) Drug-induced reinstatement of heroin-and cocaine-seeking behaviour following long-term extinction is associated with expression of behavioural sensitization. *Eur J Neurosci* 10: 3565-3571.
119. De Vries TJ, Schoffelmeer ANM, Binnekade R, Vanderschuren LJMJ (2002) Relapse to cocaine-and heroin-seeking behavior mediated by dopamine d2 receptors is time-dependent and associated with behavioral sensitization. *Neuropsychopharmacology* 26: 18-26.
120. Lett BT (1989) Psychopharmacology repeated exposures intensify rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. *Psychopharmacology (Berl)* 98: 357-362.
121. Mendrek A, Blaha CD, Phillips AG (1998) Pre-exposure of rats to amphetamine sensitizes self-administration of this drug under a progressive ratio schedule. *Psychopharmacology (Berl)* 135: 416-422.
122. Valadez A, Schenk S (1994) Persistence of the ability of amphetamine preexposure to facilitate acquisition of cocaine self-administration. *Pharmacol Biochem Behav* 47: 203-205.
123. Brown RM, Short JL, Lawrence AJ (2010) Identification of brain nuclei implicated in cocaine-primed reinstatement of conditioned place preference: A behaviour dissociable from sensitization. *PLoS One* 5: 15889.
124. Borgland SL, Taha SA, Sarti F, Fields HL, Bonci A (2006) Orexin in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. *Neuron* 49: 589-601.
125. Macedo GC, Kawakami SE, Vignoli T, Sinigaglia-coimbra R, Suchecki D (2013) The influence of orexins on ethanol-induced behavioral sensitization in male mice. *Neurosci Lett* 551: 84-88.
126. Li Y, Li S, Sui N, Kirouac GJ (2009) Orexin-A acts on the paraventricular nucleus of the midline thalamus to inhibit locomotor activity in rats. *Pharmacol Biochem Behav* 93: 506-514.
127. Quarta D, Valerio E, Hutcheson DM, Hedou G, Heidbreder C (2010) The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization. *Neurochem Int* 56: 11-15.
128. Mcpherson CS, Featherby T, Krstew E, Lawrence AJ (2007) Quantification of phosphorylated cAMP-response element-binding protein expression throughout the brain of amphetamine-sensitized rats: Activation of hypothalamic orexin a-containing neurons. *J Pharmacol Exp Ther* 323: 805-812.
129. Winrow CJ, Tanis KQ, Reiss DR, Rigby AM, Uslaner JM, et al. (2010) Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure. *Neuropharmacology* 58: 185-194.
130. Smith RJ, Aston-jones G (2012) Orexin/hypocretin 1 receptor antagonist reduces heroin self-administration and cue-induced heroin seeking. *Eur J Neurosci* 35: 798-804.
131. Boutrel B, Cannella N, Lecea L De (2010) The role of hypocretin in driving arousal and goal-oriented behaviors. *Brain Res* 1314: 103-111.
132. Chen Q, Lecea L De, Hu Z, Gao D (2015) The hypocretin/orexin system: An increasingly important role in neuropsychiatry. *Med Res Rev* 35: 152-197.
133. Brisbare-roch C, Dingemans J, Koberstein R, Hoever P, Aissaoui H, et al. (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. *Nat Med* 13: 150-155.
134. Steiner MA, Lecourt H, Jenck F (2013) The dual orexin receptor antagonist almoxexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. *Int J Neuropsychopharmacol* 16: 417-432.
135. Smart D, Brough SJ, Jewitt F, Johns A, Porter RA, et al. (2001) SB-334867-A: The first selective orexin-1 receptor antagonist. *Br J Pharmacol* 132: 1179-1182.
136. Steiner MA, Gatfield J, Brisbare-roch C, Dietrich H, Treiber A, et al. (2013) Discovery and characterization of ACT-335827, an orally available, brain penetrant orexin receptor type 1 selective antagonist. *ChemMedChem* 8: 898-903.
137. Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, et al. (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX 2 receptor. *Br J Pharmacol* 156: 1326-1341.
138. Fitch TE, Benvenga MJ, Jesudason CD, Zink C, Vandergriff AB, et al. (2014) LSN2424100: A novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy. *Front Neurosci* 8: 5.
139. Cason AM, Aston-jones G (2013) Attenuation of saccharin-seeking in rats by orexin/hypocretin receptor 1 antagonist. *Psychopharmacology (Berl)* 228: 499-507.
140. Brown RM, Lawrence AJ (2013) Ascending orexinergic pathways and alcohol-seeking. *Curr Opin Neurobiol* 23: 467-472.
141. Thompson JL, Borgland SL (2011) A role for hypocretin/orexin in motivation. *Behav Brain Res* 217: 446-453.
142. Heydendael W, Sengupta A, Beck S, Bhatnagar S (2014) Optogenetic examination identifies a context-specific role for orexins/hypocretins in anxiety-related behavior. *Physiol Behav* 130: 182-190.
143. Kukkonen JP (2012) Recent progress in orexin/hypocretin physiology and pharmacology. *Biomol Concepts* 3: 447-463.
144. Dubey AK, Handu SS, Mediratta PK (2015) Suvorexant: The first orexin receptor antagonist to treat insomnia. *J Pharmacol Pharmacother* 6: 118-121.
145. Vittoz NM, Berridge CW (2006) Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: Involvement of the ventral tegmental area. *Neuropsychopharmacology* 31: 384-395.
146. Vittoz NM, Schmeichel B, Berridge CW (2008) Hypocretin/orexin preferentially activates caudomedial ventral tegmental area dopamine neurons. *Eur J Neurosci* 28: 1629-1640.



Journal of Anesthesia & Clinical Care
Journal of Addiction & Addictive Disorders
Advances in Microbiology Research
Advances in Industrial Biotechnology
Journal of Agronomy & Agricultural Science
Journal of AIDS Clinical Research & STDs
Journal of Alcoholism, Drug Abuse & Substance Dependence
Journal of Allergy Disorders & Therapy
Journal of Alternative, Complementary & Integrative Medicine
Journal of Alzheimer's & Neurodegenerative Diseases
Journal of Angiology & Vascular Surgery
Journal of Animal Research & Veterinary Science
Archives of Zoological Studies
Archives of Urology
Journal of Atmospheric & Earth-Sciences
Journal of Aquaculture & Fisheries
Journal of Biotech Research & Biochemistry
Journal of Brain & Neuroscience Research
Journal of Cancer Biology & Treatment
Journal of Cardiology: Study & Research
Journal of Cell Biology & Cell Metabolism
Journal of Clinical Dermatology & Therapy
Journal of Clinical Immunology & Immunotherapy
Journal of Clinical Studies & Medical Case Reports
Journal of Community Medicine & Public Health Care
Current Trends: Medical & Biological Engineering
Journal of Cytology & Tissue Biology
Journal of Dentistry: Oral Health & Cosmesis
Journal of Diabetes & Metabolic Disorders
Journal of Dairy Research & Technology
Journal of Emergency Medicine Trauma & Surgical Care
Journal of Environmental Science: Current Research
Journal of Food Science & Nutrition
Journal of Forensic, Legal & Investigative Sciences
Journal of Gastroenterology & Hepatology Research
Journal of Gerontology & Geriatric Medicine
Journal of Genetics & Genomic Sciences
Journal of Hematology, Blood Transfusion & Disorders
Journal of Human Endocrinology
Journal of Hospice & Palliative Medical Care
Journal of Internal Medicine & Primary Healthcare
Journal of Infectious & Non Infectious Diseases
Journal of Light & Laser: Current Trends
Journal of Modern Chemical Sciences
Journal of Medicine: Study & Research
Journal of Nanotechnology: Nanomedicine & Nanobiotechnology
Journal of Neonatology & Clinical Pediatrics
Journal of Nephrology & Renal Therapy
Journal of Non Invasive Vascular Investigation
Journal of Nuclear Medicine, Radiology & Radiation Therapy
Journal of Obesity & Weight Loss
Journal of Orthopedic Research & Physiotherapy
Journal of Otolaryngology, Head & Neck Surgery
Journal of Protein Research & Bioinformatics
Journal of Pathology Clinical & Medical Research
Journal of Pharmacology, Pharmaceutics & Pharmacovigilance
Journal of Physical Medicine, Rehabilitation & Disabilities
Journal of Plant Science: Current Research
Journal of Psychiatry, Depression & Anxiety
Journal of Pulmonary Medicine & Respiratory Research
Journal of Practical & Professional Nursing
Journal of Reproductive Medicine, Gynaecology & Obstetrics
Journal of Stem Cells Research, Development & Therapy
Journal of Surgery: Current Trends & Innovations
Journal of Toxicology: Current Research
Journal of Translational Science and Research
Trends in Anatomy & Physiology
Journal of Vaccines Research & Vaccination
Journal of Virology & Antivirals
Archives of Surgery and Surgical Education
Sports Medicine and Injury Care Journal
International Journal of Case Reports and Therapeutic Studies

Submit Your Manuscript: <http://www.heraldopenaccess.us/Online-Submission.php>